BIOHIT HealthCare is pleased to announce its partnership with Celltrion Healthcare UK Ltd, providing point-of-care assays for the Celltrion Connect Dedicated Homecare Service, which is designed to seamlessly support patients with inflammatory bowel disease (IBD) and their healthcare providers. BIOHIT will be supplying the Preventis SmarTest® Calprotectin Home test – a digital self-test system that combines a faecal calprotectin test with a smartphone app to help patients to monitor their condition in the comfort of their own homes.
The new service has been set up in response to NHS demands and offers a unique 360 degree care package to support IBD patients who have been prescribed Remsima® SC (infliximab). It also provides ongoing education and support from fully dedicated, experienced, specialist nurses – to ensure patients get the most from their medication and achieve the best possible outcomes while on this therapy – and high quality prescription management, dispensing and delivery services.
BIOHIT supplies the Preventis SmarTest® Calprotectin Home test, a digital self-test system
and smartphone app that allow patients to monitor their condition at home.
As part of this care initiative, the SmarTest® rapid lateral flow device will be delivered to patients three times a year for instantaneous snapshots of their disease. A quantitative measurement of faecal calprotectin levels and assessment of disease activity via patient-reported symptoms are recorded using the SmarTest Calprotectin Home app. The results are then automatically sent to the patient’s clinical team within the associated healthcare organisation, so that clinicians can monitor their patients’ conditions remotely with confidence.
Graham Johnson, Managing Director at BIOHIT Healthcare, commented: “We are delighted to support the Celltrion Connect programme with SmarTest®, an intuitive self-test that is ideally suited to this model of care to truly benefit IBD patient management and outcomes.”
Matt Eddleston, Commercial and Operations Director at Celltrion Healthcare UK Ltd, added: “The partnership with BIOHIT to provide SmarTest is another example of Celltrion Healthcare’s patient centricity, and reflects our desire to truly create value for all the customers we serve.”
For more information about the SmarTest Calprotectin Home test, please visit
About BIOHIT HealthCare Ltd
BIOHIT HealthCare Ltd (www.biohithealthcare.co.uk) is part of the Finnish public company, BIOHIT OYJ, which specialises in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases. The company's many unique and patented diagnostic tests transform clinical practice and make screening, diagnosis and monitoring of gastrointestinal diseases efficient and cost effective. Non-invasive diagnostics are at the core of BIOHIT's offering, making it the provider of choice for leading gastroenterologists and laboratory scientists worldwide.